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In this review, we attempt to distill our thoughts regarding the study of the interaction of 
luminal fluids with the drug-matrix interface, a subject close to SandyÕs long-term research 
interests enveloping excipients, lipids, drug absorption mechanisms and innovative 
formulation approaches.  The interests of our panel of writers, stimulated by some of 
Professor FlorenceÕs earlier work, has prompted us to review how much of the absorption 
process can be understood in terms of simple physicochemical mechanisms, processes that 
will allow us to examine the idiosyncrasies of compounds and formulations in complex 
matrices, representing food and the changing states of secretions. This paper is our 
contribution to the special edition of the International Journal of Pharmaceutics in honour of 
Professor Alexander Florence, a friend and a mentor for many years.  
 
The rate of appearance and, in some cases, the total quantity of an active pharmaceutical 
ingredient found in the systemic blood after oral administration is related to the ability to 
form a solution of the drug in the contents of the gastrointestinal lumen (Nelson, 1957).  
Although the physicochemical properties and basic aqueous solubility of the drug are key 
drivers in this process, it has been appreciated for some time that simple in vitro aqueous 
solubility is a poor predictor of in vivo gut solubility (Dressman et al., 2007).  The 
biopharmaceutical importance of this discrepancy increases inversely in relation to the 
dose/solubility ratio of the API, as expressed in the Developability Classification System 
(Butler & Dressman 2010). Achieving solubility in poorly mixed gut luminal fluids is a 
complex phenomenon but two features are important: the drugÕs physicochemical properties 
and the influence of both natural and excipient based surfactants in sustaining solubility of 
the API as the luminal composition changes. Professor Florence has contributed to the study 
of these aspects and ongoing research has attempted to fill in some of the gaps in our 
knowledge by the development of new instrumentation. The results from investigations 
collected with the new technology are being gradually being integrated into in silico models 
of the dissolution process.  The consolidation of ÔrulesÕ from the study of dissolution of API in 
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luminal fluids is complicated because fluids vary in composition between individuals, 
influenced by diet, drug exposure and disease. The impact in some cases will be minor 
whereas for some chemical classes they will be significant. Moreover, the fluids are complex 
media that alter as they travel down the gut and different structures form.  This is especially 
true for the fed state where additionally, mechanical forces are applied to the food matrix to 
aid dispersion and increase surface area for enzymatic action. Oral formulations are 
subjected to altered (increased) mechanical forces when taken with food and therefore such 
conditions need to be simulated in laboratory-based tests. 
 
The gastrointestinal tract is a muscular tube whose role is the reduction of the food 
matrix to a slurry, the secretion of enzymes and the absorption of the separated, useful 
components from chyme. For many nutrients, the absorption is an active process 
since the products of digestion are small and polar and the nature of the epithelium is 
a lipoid barrier. Thus absorption is always likely to be slow process, requiring energy 
and the diversion of blood to transport the nutrients to the liver and beyond. The 
calorific gain from intake of carbohydrate to fat varies over a three-fold range. The 
components embedded in meat, grain and fat from this omnivorous diet taken in as a 
single meal is stored in the stomach to be supplied to the intestine at an optimised 
rate. Through hormonal mechanisms and sampling high in the gastrointestinal tract, 
the contact time with the absorbing membrane is regulated to facilitate maximum 
efficiency of digestion according to the size and type of meal. In addition, the 
components may require extensive mastication or mixing movements of muscle to 
lubricate the food mass and to allow more dispersion.  Not too far back in our 
evolution, man was a nomadic hunter-gatherer and warrior, and food was distinctly 
unprocessed and fibre rich.  The gut therefore had to work hard to separate useful 
material from a diverse matrix and protect against the occasional poisons from the 
seeds of berries and fruits which might be accidentally ingested. The evolution of the 
gastrointestinal tract has resulted into a gut specialized into segments, with an acid 
sump to coagulate proteins followed by a duodenum in which the luminal contents 
are adjusted towards neutrality and bile added to emulsify fats. The dispersed material 
is then digested, resulting in a gradual loss of volume leaving some useful but ÔlockedÕ 
nutrients to be extracted through bacterial action.  To shield the liver from insult, 
behavioral and sensory mechanisms developed to avoid retention of poisons; 
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transporter mechanisms became evident to reduce exposure and detoxifying enzymes 
inducible to aid excretion of the xenobiotics.    
 
It can be immediately appreciated that the gut is actively monitoring the composition of 
ingested material. Drugs have almost no nutritional value and mechanisms that help us to 
protect ourselves from poisons come into play: specifically taste and the vomiting reflex have 
to be intentionally bypassed by disguise of the API in a formulation. That work then has to be 
undone further down the gut to achieve the anticipated drug concentration -time exposure.  
 
The analytical task we face is how to make continuous measurements in a murky 
media, whose composition changes along the gastrointestinal tract (Dressman et al., 
2007). Within the darkness of the gut, phenomena such as disintegration, super-
saturation, precipitation and dissolution are occurring in unidentified segments. The 
impact of variability is to necessitate the performance of expensive clinical trials and 
to slow medicine development, a situation that should be avoided if necessary. The 
simulated biological fluids that are used in pharmaceutical sciences are evolving 
recipes and for some media, considerable differences exist as exemplified by the 
formulae, as reviewed by Marques and colleagues. For example, simulated saliva, 
which in five recipes, differs in electrolyte composition and the presence or absence 
of mucin (Marques et al., 2011). The importance of mucin is more apparent in 
considering a food matrix rather than medications, since salivary mucin induces 
flocculation of some emulsions, probably changing sensory perception (Vingerhoeds 
et al., 2005). It is however essential to assist the normal swallowing reflex. 
 
Tasting and judging whether you can swallow a medicine.  
Except for specially designed formulations, which may be administered to bypass the 
first pass effect or to directly treat the mouth, an early task is to assess the acceptability 
of the dosage form.  We apply different judgments according to the physical state of 
the material. For example, a strange colored clear liquid will be sampled by judging 
acidity, saltiness, bitterness, sweetness, effervescence, the presence of off-flavors and 
the smell that we perceive during ingestion. The process of swallowing involves a 
voluntary oral phase, where the tongue samples the ingested material and the person 
makes a decision about whether it can be swallowed. Difficulty in swallowing 
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medications is a commonly reported problem but although phagophobia, a perceived 
risk of choking in the absence of a physiological explanation is rare in patients, it has 
been reported in HIV sufferers who have a high oral dose burden (Duggan et al., 
2014).  Saliva needs to be present as a lubricant and pools in the mouth below the 
tongue and on the cheek- gum boundary. The dosage form is usually moistened by 
the action of the tongue pressing the dosage form against the palate and then moving 
it backwards, contained in a depression formed in the tongue. Food is usually chewed 
and moistened with saliva to form a bolus for swallowing and if the tongue senses the 
food is too dry; the swallow will be aborted.  The wetted bolus is presented to the 
back of the mouth, stimulating the palatal receptors and touch receptors of the 
pharynx (Gleeson, 1999). Pharyngeal peristalsis imparts a forward velocity of a 
swallowed bolus >0.3m/s as measured by video fluoroscopy. In patients with 
dysphagia, increasing the viscosity of the bolus to Ôpudding consistencyÕ ( 3682 mPa.s) 
was associated with more efficient swallowing (Clav et al., 2008). Surprisingly, thin 
liquids present special problems for patients with neurological disease.  For solid 
formulations that will be swallowed, still more decisions based on shape factors and 
surface feel become at issue.  
 
As yet, our success in replicating mouth sensations is limited. Taste perception is 
modulated by various factors including aging, gender, ethnicity, cigarette smoking, 
olfactory stimuli [as well as the temporary loss of smell sense during a cold], time of 
day and even psychological processes.  As we get older, we lose the ability to detect 
salty and bitter substances whereas the thresholds for sour or sweet stimuli appear to 
be unchanged up to the age of 90 (Mojet et al., 2001). 
 
Swallowing medicines 
At the present time, we do not have in vitro systems for testing the ability to swallow a 
formulation.  Professor Florence was interested in the phenomenon of tablet adhesion, 
especially precipitated by concerns relating to early osmotic tablet formulations. Swisher and 
colleagues at ALZA described a method of evaluating adhesion of tablets and capsules to the 
isolated dog and pig oesophagus and ranked the forces of adherence for different 
formulations (Swisher et al., 1984). Florence and colleagues used the same methodology at 
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Strathclyde University to examine tissue adhesion of tablets and hard-shell capsules showing 
that film coated tablets had low adhesion (Al-Dujaili , 1986). These data are generally 
supported by in-vivo measurements in man using gamma scintigraphy. As we age, there is a 
noticeable decrease in the efficiency of muscular coordination, coupled with muscle 
weakness tendon stiffness and a loss of motor control. Significantly, impaired transit in the 
elderly can be readily demonstrated scintigraphically which is of particular relevance for 
formulations containing irritant drugs (Perkins et al. 1994; ibid 2001). Dr. Stegeman has 
made an extensive study of the problems in this age group with regard to swallowing 
medicines and has proposed that attention to appropriate dosage forms for the elderly will 




Functionally the stomach divides into two chambers on eating, the upper part (the fundus) 
relaxing to accommodate the food.  In the body, propagating muscular contractions 
becoming stronger below the midline of the stomach cause contractions against a partially 
closed pyloric sphincter, sieving solids and liquids.  Acid is formed by secretion aided by the 
increased hormonally driven blood flow. The duodenum plays a role as a sensor and by 
modulating the wall pressure difference between the duodenum and the pylorus, the 
dispersed material enters as an approximately isocaloric load. 
 
After a meal, the matrix distributed in the stomach is non-uniform, with channels of 
liquid travelling around consolidating food masses, which are stacked from the greater 
curvature and as food is digested, small particles empty with the liquid phase. It has 
been generally accepted that preparations that dissolve or form particles of less than 2 
mm in diameter pass through the stomach in a similar fashion to liquids and are less 
likely to be influenced by gastroparesis (Pohle & Domschke 2003).  Particles can 
empty as boluses, mix in with the food, or partially stratify according to when during 
the meal the formulations are consumed (OÕReilly et al., 1987). 
 
All fluids in the gut have a lower surface tension than water and Fell & Mohammed reported 
that gastric juice was more effective than bile at wetting a powder sample of phenobarbitone 
(Fell & Mohammed, 1995), an extension of the observations almost a decade earlier of 
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Finholt & Solvang, who described the role of surface tension on dissolution kinetics of 
phenacetin and phenobarbitone in polysorbate-hydrochloric acid media (Finholt & Solvang, 
1968).  At the same time as John FellÕs work in Manchester, Efentakis and Dressman were 
rediscovering some of the data known to gastroenterologists and applying it to 
biopharmaceutical purposes. They reported that aspirated gastric samples had a pH between 
1 and 2 with a measured surface tension of between 35 and 45 mM/m (Efentakis and 
Dressman, 1998). 
 
For a drug formulation, the key factors are a dynamic change in the media reflecting the 
balance of dilution, secretions and buffering by the food (especially protein) and the erosive 
forces which are applied during trituration of intact objects by contractions in the distal 
stomach. These conditions are not mimicked in any compendial apparatus and in order to 
get a more realistic simulation of the conditions in the human stomach in a physical 
simulator, there must be attention to the nature of the gut fluids, the volume changes, the pH 
gradient occurring in the stomach and the periodic forces applied to the formulation. During 
emptying, the stomach changes shape although this factor is rarely considered; it is however 
of importance for floating dosage forms. 
 
There have been many attempts to mimic the upper gastrointestinal tract. First this was 
because it was seen as the easiest task: the stomach can be directly observed during 
endoscopy and we can sample the stomach and the duodenal contents through a tube. 
Measurements of fluids further down the GI tract require more invasive clinical attention. 
The residence time in the stomach is an important determination determinant of the onset of 
the arrival of the drug in the plasma and therefore drug action. In addition, disintegration in 
the stomach might result in dose dumping (especially in the presence of food) and the 
degradation of drug in gastric acid prior to absorption. Simple models are based on a fixed 
volume compartment; for example, the modified Rossett and Rice apparatus used by our 
group to test floating antacids (Washington et al., 1985). More complex models join multiple 
compartments, arranging transfer of fluid across conditions representing gastro-duodenal 
exchange with changes in pH. Others apply force periodically to the formulation for example 
the TNO simulator (TIM-1). One apparatus described by Garbacz and colleagues applies 
periodic pressure and takes the formulation in and out of contact with fluid (Garbacz et al., 
2008). In most of these systems, complex media can be used but there is always an issue 
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with regard to turbidity and media which have high optical absorbance. In spite of these 
reservations, a prediction based on performance in such apparatus is generally superior to 
that seen in compendial apparatus based on acids and buffers. 
 
Parts or all of an oral formulation must dissolve in the gastrointestinal contents and the active 
pharmaceutical ingredient pass from lumen to the absorbing surface.  Drugs are not absorbed 
to any great extent in the stomach and therefore the rate of entry into the duodenum controls 
the onset of action of immediate release, well-absorbed drugs.  As a consequence, there is 
little need for extensive in vitro examination and simple measures such as disintegration time 
may be sufficient to characterise the API release from the dosage form in a conventional 
dissolution apparatus. In contrast, sustained-release formulations may encounter situations 
which cause altered release; for example, those formulations which are sensitive to alcohol.  
Here, the physical presentation of the dose form may be responsible for important differences 
in robustness. As an example, physical compression of the dosage form occurs in the distal 
stomach, which may be sufficient to cause structural weaknesses in an intact formulation 
exposed to ethanol Ð containing media. 
 
In most cases, the interest centres on the processes during the transfer of the formulation from 
stomach to intestine. Changes in solubility stimulated by pH may cause precipitation; if this 
is avoided by supersaturation i.e. in the presence of an excipient, then careful examination of 
the process to maximise passive Fickian drive maybe justified.  Such a process does lend 




In the intestine, the glandular secretory epithelium of the stomach abruptly alters to an 
absorptive epithelial lining with deep folds and villi.   Neutralisation of gastric acid occurs in 
the shortest section of the intestine and transit through the duodenal region is quick Ð 
typically less than five minutes.    In fasted conditions, formulations are moved through the 
intestinal by waves of contraction originating from the fundal region, propagated through to 
the terminal ileum.   In clinical trials where the volunteer remains fasted, stasis of the 
formulation can often be seen in the ileum about two to three hours after ingestion: most 
water has been absorbed and shear forces are probably low.  Feeding causes many 
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physiological changes including increased splanchnic blood flow to the upper GI regions, fat 
intake release of bile and changes in the intestinal motility to generate more segmenting 
movements. Dietary fat is an essential substrate in a variety of functions including energy 
supply and vitamin absorption.   During this time there will be movement of water across the 
gut wall as food is broken down to small more osmotically active fragments causing 
secretion and small nutrient absorption occurs with water drag of the solutes. 
 
For dissolution and disintegration processes, the aspects regarding absorption, 
transporters and efflux are not important although there have been attempts to 
combine models which utilise all the information. Generally, suitable cell lines are 
used to characterise apical and basal transfer of API from and into the lumen. In silico 
models are then constructed which utilise all of the information available in order to 
make predictive simulations. Improvement of biorelevant dissolution fluids and 
apparatus, which sequentially exposes the drug to differences in luminal composition, 
suffice to examine rates of dissolution of a particular drug. Thus, for conventional 
drugs which follow solute-dominated pathways and partition across membranes, the 
perspective for optimized in vitro approaches is high.  This is the objective of the Oral 
biopharmaceutics tools Initiative, a collaborative venture between industry and 
academia to develop new instrumentation and computer models, attempting to fill 
knowledge gaps relating to oral drug delivery (Lennerns et al, 2014). Recent 
research in the OrBiTo program has attempted to more closely define the composition 
of fluids in the distal gut in order to be able to improve biorelevance. 
 
Solubility, Dissolution, Surfactants and Gut contents   
A drugÕs solid state properties such as particle size or crystalline form (as a polymorph 
or hydrate) influence the initial dissolution rate and can lead to the generation of 
supersaturated solutions with solubility greater than the equilibrium value (Shefter & 
Higuchi, 1963).  The control and modification of both particle size and crystalline 
form using processes such as comminution therefore can be employed to influence 
dissolution of poorly soluble drugs such as digoxin and steroids (Florence & Salole, 
1976).  The provision of bile salts as natural surfactants to assist in the digestion of fats 
on drug dissolution was recognized by Borgstrom. He proposed a possible role of bile 
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as the medium responsible for increasing the solubility of drugs and other water 
insoluble substances in gastrointestinal fluid by generation of micellar solutions 
(Borgstrom, 1962).  The micellar assembly of surfactants, the thermodynamic driving 
forces for this and the ability of these systems to solubilise drugs and impact on 
formulation problems has been a constant theme of Professor FlorenceÕs research 
(Elworthy & Florence 1963, Elworthy, Florence & Macfarlane 1968, Attwood & 
Florence 1983).  Even in these early publications, it was recognized that, Òthe use of 
solubilizers in pharmacy to increase the solubility of sparingly soluble drugs has wide 
implications, and it is important that these are understoodÓ, a task that continues 
today ( Khadra et al., 2014, Fuchs et al., 2015).   
 
Endogenous Surfactants in the Gut 
The impact of bile salts on drug solubility in the gut was an early area of 
biopharmaceutical research with studies indicating that dissolution of poorly soluble 
drugs was enhanced in the presence of bile salts (Bates et al., 1966a), a result of such 
importance that it warranted publication in a high impact journal!  Studies also 
indicated that solubilisation capacity was bile salt concentration dependent and 
influenced by the bile salt employed.  Additionally, digestion products for example 
phospholipids and fatty acids impact on gut solubility and therefore the bioavailability 
of poorly soluble drugs (Charman et al., 1993).   
Interest in the role of the gut microbiome in health and disease has revealed  
significant signaling effects of bile acids on the composition of the colon microbiota, 
in addition to direct effects on the membrane G-protein coupled receptors which 
regulate several host pathways (Wahlstrm et al., 2016). Short term changes in diet, 
e.g.  to entirely animal or vegetarian sources overwhelms the balance of the 
microbiota and bacteria, viruses and fungi from the new dietary source transiently 
colonises the colon (David et al., 2014).  This indicates a dynamic balance between 
surfactant presentation and the diversity of our microbial lodgers. If we add to this 
scenario the exposure to mixes of natural and synthetic surfactants, some of which 
will travel unaltered to the colon, it will be appreciated that opportunities for 
surfactant-microbiome interactions are yet to be discovered (see Figure 1).  
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Figure 1 near here. 
 
Surfactants in Dissolution 
In 1897 Noyes and Whitney published the first analysis of the dissolution of sparingly 
soluble compounds and introduced a mathematical analysis demonstrated that the 
rate of solution of a solid in a bulk dissolution medium was dependent upon the 
compoundÕs saturation solubility (Noyes & Whitney,1897).  In the 1950Õs and 1960Õs, 
the biopharmaceutical implication of this relationship with respect to the oral 
administration of drugs was recognized along with examples of differences in 
bioavailability due to formulation or batch-to-batch variations in performance.  In the 
1970Õs the first pharmacopoeial dissolution tests were introduced in recognition of the 
importance of this property and in an attempt to apply quality control procedures to 
oral dosage form performance.  In 1995 Amidon introduced the Biopharmaceutical 
Classification System categorising drugs based on their aqueous solubility and 
intestinal permeability.  Compounds with a low aqueous solubility present the greatest 
formulation and biopharmaceutical challenge in vivo, and in vitro during dissolution 
testing.  For low solubility compounds, the in vitro dissolution required the 
development of media with increased solubility either through the use of solutions of 
single synthetic surfactants or simulated intestinal media (Dressman et al., 1998).  The 
former is simple and illustrate that increased solubility through non-ionic surfactants 
such as polysorbate 80 increases dissolution, although the surfactant will also affect 
surface wetting (Mysels & Florence 1970).  Biorelevant media which mimic the 
natural surfactants and conditions present in the gut are complex mixtures 
incorporating bile salt, lecithin, fatty acid and monoglyceride and it is possibly not 
surprising that multiple recipes and interations have been examined during attempts 
to develop correlations between in vivo performance and in vitro dissolution (Fuchs et 
al., 2015).  Early studies also indicated that this was a complex phenomenon with 
mixtures of endogenous surfactants exhibiting solubility variations that were drug and 
mixture specific (Bates et al., 1966b).  There is a complex interplay between the drug 
and surfactant system (Reymond & Sucker, 1988) and research into this relationship 
continues. 
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In-vitro characterisation of lipid-based formulations (LBFs) presents significant 
challenges and a simple phosphate buffer dissolution experiment is often not 
representative of the complex environment of the small intestine. In response to lipid 
ingestion, secretions of pancreatin and bile salts from pancreas and gall bladder 
respectively work to digest the lipids, creating a digestion product composed of mixed 
micelles and bile salt complexes.  These mixed micelles act to preserve the drug 
molecule in the solubilised state and can carry the drug to the site of absorption in the 
small intestine. For this reason, the representation of the gut in the beaker, particularly 
the small intestine, requires a more complex media and enzymatic reactions are 
required to be taken into account particularly for lipid-based formulations.  
Representative in-vivo characterisation is by no means novel and historically has been 
investigated by a number of groups, with a common goal of achieving a global in-vitro 
model, which is predictive of in-vivo digestion and absorption. Typically, LBFs are 
assessed in-vitro through dispersion and digestion tests, to investigate emulsification 
behaviour and solution stability.   Initially, dispersion testing is performed in order to 
understand the stability of LBFs on dilution and likelihood of the API to precipitate 
from the emulsion.  Digestion testing is then used in an attempt to understand the 
behaviour of the API within the formulation during digestion in the intestine.   Early 
investigational work concerning digestion dates back to the 1980Õs, where data from 
in-vitro lipolysis of medium chain triglycerides (MCT) and long chain triglycerides 
(LCT) were reported (Reymond & Sucker, 1988).  Further models were then developed 
which described the solubilisation of poorly water-soluble substances during digestion 
in lipid-based formulations (Christensen et al 2004, Porter et al 2004, Cuine et al., 
2008, Sassene et al 2010, Larsen et al.,2011).  More recently, the desire within the 
scientific community to develop standardised in-vitro methods for characterisation 
and assessment of LBFs, led to the formation of the Lipid Formulation Classification 
System Consortium (LFCS Consortium). The LFCS Consortium has combined 
academics and industrial researchers to create a collaborative programme, which is 
focused on the design of LBF characterisation methods that are both physiologically 
relevant and applicable to LBF during the developmental phases, potentially leading 
through to commercialisation.  Initial work focused on the establishment of baseline 
conditions and media selection through the assessment of various LBFs, including 
type I, II, II and IV LBFs (Williams et al., 2012a) as illustrated in Table 1.   
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Table 1 near hereÉ 
 
The concentration of bile salt and drug loading has been investigated with respect to 
the generation and sustainment of supersaturation of a model poorly soluble API, 
danazol (Williams et al., 2012b). Bile salt concentration was found to influence the 
in-vitro digestion of type I and II LBFs; however, the impact of concentration on type 
III LBFÕs was not marked due to speed of digestion. In addition, danazol solubilisation 
within the digested aqueous phase increased with increasing bile salt concentration, 
up to a concentration of 3mM.  The potential for danazol to be maintained as a 
supersaturated solution within digested formulations, without precipitation, was also 
characterised.  These initial findings were expanded incorporating alternative model 
APIs fenofibrate and tolfenamic acid (Williams et al., 2013), to help confirm the 
proposal that the maximum drug supersaturation ratio (SRM) can help define the 
limitations of supersaturation in in-vitro digested LBFs.  The SRM is determined from 
the ratio of maximum theoretical API concentration in the aqueous phase following 
LBF digestion to maximum API solubility within the digested aqueous phase.  It has 
been suggested by the LFCS Consortium that in order to maintain supersaturation and 
to limit precipitation, when defining maximum API loading within LBFs the calculated 
SRM should not exceed 3.  In the final part of the series, more challenging conditions 
for the digestion test were proposed in an attempt to further understand the impact on 
maintenance of supersaturation and provide discriminatory tests between formulations 
behaving similarly with standard digestion testing (Williams et al., 2014, Bakala-
NÕGoma et al., 2015).   Following this extensive development, the methods refined by 
the LFCS Consortium have been used routinely in both academia and industry.  
Although these methods have been of great benefit, challenges remain in the 
characterisation of some LBFs, including the lack of sink conditions as would be 
expected during the absorption process, the influence of API metabolism on in-vivo 
performance and the prediction of performance of LBF suspension formulations.  
Introducing sink conditions during assessment of LBFs, whilst representing the gut in a 
beaker is particularly challenging. 
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Surfactants incorporated into the Formulation 
The application of surfactants for the solubilisation of materials can be traced back to 
the 1890Õs with studies on bile salts and soaps but it was not until the 1930Õs that 
these observations were related to the thermodynamically formed colloidal micellar 
phase.  The study of surface tension lowering excipients in pharmaceutical systems 
started with poorly soluble steroid hormones (Ekwall & Sjoblom, 1949) but as 
reviewed by Elworthy, Florence and Mcfarlane in 1968 and again in 1983 (Attwood 
and Florence) rapidly expanded to cover multiple drugs, dosage routes and 
solubilisation systems.  Initial application in medicines development was limited by 
the systemic toxicity of the ionic surfactant systems available and it was only on the 
development of the less toxic non-ionic surfactants that wider pharmaceutical 
application of solubilized formulations was possible.  The physicochemical 
characterisation of non-ionic surfactants is a research area that was initiated by Sandy 
and has been a continual focus of his career.  The solubilisation and formulation of 
poorly drugs in surfactant systems was reviewed by Professor Florence in 1981 and 
this work providing more detail on the influence of the hydrocarbon portion of non-
ionic surfactants on solubilisation (Florence 1981a).  Since that initial review, the 
number of surfactants available and systems studied has expanded considerably and 
along with ÒsimpleÓ micellar solubilisation, polymeric micelles and lipid based drug 
delivery systems (LBDDS) have been developed (Cannon & Long 2008).  Several 
marketed products incorporate this approach; for example, cyclosporine formulations 
utilize either corn or olive oil with mixtures of various non-ionic surfactants.  
Polymeric micelles formed using block co-polymers have mainly been applied to 
parenteral systems and can be employed for controlled release (Law, Florence & 
Whateley 1986).  The chemical variability associated with surfactants and the 
development of chemical coupling systems permits the generation of new 
supramolecular surfactant-polymer systems. (Al-Jamal, Sakthivel& Florence, 2005).  
It is not yet known if these systems will find utility in marketed oral dose products.    
 
Surfactants, enhanced absorption and toxicity 
The ability of non-ionic surfactants which are present in a formulation to enhance the 
oral absorption of drugs, over and above that associated with solubilisation, has been 
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previously reported in the literature (van Hoogdalem, de Boer & Breimer 1989).  
This property is most obvious with drugs which would normally have low or 
negligible bioavailability when administered orally, for example the oral absorption of 
methotrexate can be increased by co-administration with polysorbate 80 (Azmin et al 
1982).  There is however no molecular specificity in this effect and the absorption of 
poisons is equally promoted to that of the drug (Walters, Dugard, & Florence 
1981).  The magnitude of this effect is surfactant concentration-dependent and is 
linked to the presence of surfactant monomers in solution, leading to activity below 
the critical micelle concentration (CMC).  Above the CMC, solubilisation into the 
micelle reduces the effect (Florence 1981b) whilst the free monomer concentration is 
constant.  The effect is due to an interaction of the free surfactant monomers with the 
gut wall epithelial lining.  As discussed previously, the membrane is a complex 
structure consisting of multiple lipid components and proteins. Penetration of the 
hydrophobic portion into the outer surface of the bilayer disturbs function, increasing 
absorption.  This effect can be applied in multiple drug delivery problems to enhance 
absorption or tissue penetration (Kerr et al., 1987).  However, the negative effect of 
this interaction is the potential toxicity to the normal physiological function of the 
membrane (Baillie et al., 1989), which will have to be balanced against increased 
bioavailability.  Additionally, since the surfactants are not selective, the ÒreductionÓ of 
barrier function will not be specific and may also increase the availability of 
potentially toxic agents from the gut (Al-Jamal, Sakthivel & Florence, 2005).   
 
Surfactants: the future 
Since the early studies on the influence of surfactants, including natural or synthetic 
substances, the knowledge base concerning the absorption of poorly soluble drugs 
from the gut has expanded considerably.  Professor FlorenceÕs multiple and varied 
contributions to this field have provided important foundations. 
The role of endogenous surfactants such as bile salts, phospholipids and fatty acids 
(either free or esterified) has been rationalized and simulated dissolution media 
encompassing fasted and fed states are available. These can be employed to examine 
the dissolution of poorly soluble drugs and formulations to provide a degree of in vivo 
prediction.  However, the limitations of these systems is apparent (Bergstrom et al., 
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2014) and in vivo studies expose the boundaries of current knowledge with respect to 
the composition of gut fluids (Riethorst et al., 2016) and reveal the impact this might 
have on solubilisation and absorption.   
The availability and use of the non-ionic surfactants, as formulation excipients for 
drug delivery by all routes has expanded massively in the half-century since Professor 
Florence published his first manuscript in the field.  The use of surfactants in oral 
formulations either alone, in combination or with lipid-based excipients is now 
established with multiple marketed formulations for poorly soluble drugs based on 
these systems.  Current research is focused on expanding this armamentarium with 
more novel combinations of hydrophilic entities with the almost standard 
hydrophobic long chain fatty acids.   
Whilst the experimental knowledge base has expanded, the theoretical models 
available to determine the nature and extent of the interactions between a surfactant 
and a poorly soluble molecule in a largely aqueous system remain rooted in basic 
thermodynamics.  A comprehensive treatment of the situation is complicated by the 
chemical variability of the surfactants (the nature of the hydrophobic and hydrophilic 
groups), the inherent concentration and component variability of the gut.  These are 
complex systems and it has long been recognized that phase changes and anisotropic 
behavior are normal which increase the difficulty in prediction of performance . The 
challenge for the next half century must be to develop a suitable predictive theoretical 
framework, a situation presaged by Professor Florence in 1968 when he wrote with 
respect to surfactants that Òa great deal of work using modern methods is still required 
to clarify the situationÓ (Florence, 1968). 
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Table 1. Types of LBF as proposed by the LBF Consortium (adapted from Williams 
2012a) 
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Figure 1 & Graphical abstract. Presentation of surfactants to the gut shows dynamic 
alterations in composition, reflecting digestion of fats, release of excipients  and 
absorption along the gut  
